Table 1.
Critical reagents used in the anti-EBOV GP IgG ELISA.
Table 2.
Method feasibility study: Summary of success rates based upon %CV criteria and number of dilutions that met the %CV criteria.
Fig 1.
Sample of fitted modified 4PL model for a single plate with human RS/conjugate.
RS displayed in black, NHP TS/QC in blue, human TS/QC in red.
Fig 2.
Sample of fitted modified 4PL model for a single plate with NHP RS/conjugate.
RS displayed in black, NHP TS/QC in blue, human TS/QC in red.
Fig 3.
No pattern to studentized residuals plotted against predicted values from the modified 4PL model for all plates with human RS/conjugate indicates good fit.
RS displayed in black, NHP TS/QC in blue, human TS/QC in red.
Fig 4.
No pattern to studentized residuals plotted against predicted values from the modified 4PL model for all plates with NHP RS/conjugate indicates good fit.
RS displayed in black, NHP TS/QC in blue, human TS/QC in red.
Table 3.
Summary of anti-EBOV GP IgG ELISA qualification results for NHP samples.
Table 4.
Summary of anti-EBOV GP IgG ELISA partial validation parameters, acceptance criteria, and results for NHP samples.